Pneumonia Therapeutics Global Market Report 2025

The pneumonia therapeutics market size has grown rapidly in recent years. It will grow from $10.35 billion in 2024 to $11.49 billion in 2025 at a compound annual growth rate (CAGR) of 11%. The growth in the historic period can be attributed to the increasing prevalence of drug-resistant strains, rising awareness of pneumonia prevention, growth in elderly and immunocompromised populations, expanded vaccination programs, and improvements in healthcare infrastructure.

The pneumonia therapeutics market size is expected to see rapid growth in the next few years. It will grow to $17.26 billion in 2029 at a compound annual growth rate (CAGR) of 10.7%. The growth in the forecast period can be attributed to the increasing prevalence of antibiotic-resistant strains, the rising incidence of pneumonia in aging populations, the expansion of telemedicine for early diagnosis, growing healthcare expenditures in emerging markets, increased funding for infectious disease research, and heightened awareness campaigns. Key trends expected during this period include the development of monoclonal antibodies, the adoption of inhalable antibiotics, innovations in mRNA-based vaccines, AI-driven diagnostic tools, the use of host-targeted therapies, novel immunomodulators, and advancements in rapid point-of-care diagnostic platforms.

The increasing prevalence of pneumonia is expected to drive the growth of the pneumonia therapeutics market. Pneumonia is a lung infection that causes inflammation in the air sacs, leading to symptoms such as cough, fever, and difficulty breathing. The rising incidence of pneumonia is attributed to factors including aging populations, air pollution, smoking, weakened immune systems, antimicrobial resistance, and the spread of respiratory infections such as COVID-19 and influenza. Pneumonia therapeutics are designed to combat the infection’s underlying cause whether bacterial, viral, or fungal through targeted medications while supporting recovery with oxygen therapy, anti-inflammatory drugs, and symptom management. For example, in January 2023, the National Center for Biotechnology Information reported that pneumonia affects approximately 120 million people worldwide each year, resulting in around 1.3 million deaths. Nearly 80% of pediatric pneumonia fatalities occur in children under two years old in developing nations. As a result, the growing prevalence of pneumonia is fueling the expansion of the pneumonia therapeutics market.

Leading companies in the pneumonia therapeutics market are focusing on innovative drug formulations and treatment methods to address antibiotic resistance and enhance patient outcomes. Antibiotic drugs play a crucial role in treating bacterial infections, including pneumonia. In June 2024, Orchid Pharma Limited, an India-based pharmaceutical company, collaborated with Cipla Limited, another India-based pharmaceutical firm, to introduce cefepime-enmetazobactam. This antibiotic combination is designed to treat complex infections, such as urinary tract infections (UTIs) and pneumonia, particularly those resistant to other medications. By combating bacterial resistance, it ensures more effective treatment while reducing the need for stronger antibiotics.

In August 2022, GSK plc, a UK-based pharmaceutical company, acquired Affinivax Inc. for an undisclosed amount. This acquisition allows Affinivax to continue its work under GSK’s leadership, focusing on next-generation pneumococcal vaccines. Affinivax Inc. is a US-based biopharmaceutical company specializing in developing vaccines to prevent pneumonia and other diseases caused by Streptococcus pneumoniae. This strategic move strengthens GSK’s pneumonia vaccine portfolio, reinforcing its position in the market.

Major players in the pneumonia therapeutics market are Pfizer Inc., Roche AG, Merck & Co. Inc., AbbVie Inc, Bayer AG, Sanofi S.A., AstraZeneca PLC, Abbott Laboratories, Novartis AG, GSK plc, Eli Lilly and Company, Astellas Pharma Inc., Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Cipla Inc., Hikma Pharmaceuticals PLC, Shionogi & Co. Ltd, Lupin Limited, Swedish Orphan Biovitrum AB, Nabriva Therapeutics plc, TaiGen Biotechnology Co. Ltd, Aridis Pharmaceuticals Inc., and Tergene Biotech Limited.

North America was the largest region in the pneumonia therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pneumonia therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the pneumonia therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Pneumonia therapeutics encompass treatments and medications designed to manage and treat pneumonia, a lung infection caused by bacteria, viruses, or fungi. These therapeutics work by targeting the underlying pathogens, reducing inflammation, and improving respiratory function. Treatments include antibiotics for bacterial pneumonia, antiviral drugs for viral pneumonia, and antifungal agents for fungal infections.

The main products in pneumonia therapeutics include drugs, vaccines, and oxygen therapy. Pneumonia drugs address the root cause by using antibiotics, antivirals, antifungals, and supportive treatments such as oxygen therapy. The infections treated include hospital-acquired pneumonia (HAP), community-acquired pneumonia (CAP), and ventilator-associated pneumonia (VAP). Routes of administration include oral, parenteral, and other methods, with end users spanning hospitals, home care, specialty clinics, and other healthcare facilities.

The pneumonia therapeutics market research report is one of a series of new reports that provides pneumonia therapeutics market statistics, including the pneumonia therapeutics industry's global market size, regional shares, competitors with a pneumonia therapeutics market share, detailed pneumonia therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the pneumonia therapeutics industry. This pneumonia therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The pneumonia therapeutics market consists of revenues earned by entities by providing services such as chest X-rays, blood tests, sputum culture, oxygen supplementation, mechanical ventilation, and telemedicine consultations. The market value includes the value of related goods sold by the service provider or included within the service offering. The pneumonia therapeutics market also includes sales of pneumococcal vaccines, antibiotics, nebulizers, and inhalers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values, that is, revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.